PMID- 7752851
OWN - NLM
STAT- MEDLINE
DCOM- 19950621
LR  - 20191031
IS  - 0098-2997 (Print)
IS  - 0098-2997 (Linking)
VI  - 15 Suppl
DP  - 1994
TI  - Treatment of essential hypertension with coenzyme Q10.
PG  - S265-72
AB  - A total of 109 patients with symptomatic essential hypertension presenting to a 
      private cardiology practice were observed after the addition of CoQ10 (average 
      dose, 225 mg/day by mouth) to their existing antihypertensive drug regimen. In 80 
      per cent of patients, the diagnosis of essential hypertension was established for 
      a year or more prior to starting CoQ10 (average 9.2 years). Only one patient was 
      dropped from analysis due to noncompliance. The dosage of CoQ10 was not fixed and 
      was adjusted according to clinical response and blood CoQ10 levels. Our aim was 
      to attain blood levels greater than 2.0 micrograms/ml (average 3.02 micrograms/ml 
      on CoQ10). Patients were followed closely with frequent clinic visits to record 
      blood pressure and clinical status and make necessary adjustments in drug 
      therapy. Echocardiograms were obtained at baseline in 88% of patients and both at 
      baseline and during treatment in 39% of patients. A definite and gradual 
      improvement in functional status was observed with the concomitant need to 
      gradually decrease antihypertensive drug therapy within the first one to six 
      months. Thereafter, clinical status and cardiovascular drug requirements 
      stabilized with a significantly improved systolic and diastolic blood pressure. 
      Overall New York Heart Association (NYHA) functional class improved from a mean 
      of 2.40 to 1.36 (P < 0.001) and 51% of patients came completely off of between 
      one and three antihypertensive drugs at an average of 4.4 months after starting 
      CoQ10. Only 3% of patients required the addition of one antihypertensive drug. In 
      the 9.4% of patients with echocardiograms both before and during treatment, we 
      observed a highly significant improvement in left ventricular wall thickness and 
      diastolic function.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Langsjoen, P
AU  - Langsjoen P
AD  - Institute for Biomedical Research, University of Texas at Austin 78712, USA.
FAU - Langsjoen, P
AU  - Langsjoen P
FAU - Willis, R
AU  - Willis R
FAU - Folkers, K
AU  - Folkers K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Mol Aspects Med
JT  - Molecular aspects of medicine
JID - 7603128
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Coenzymes)
RN  - 1339-63-5 (Ubiquinone)
RN  - EJ27X76M46 (coenzyme Q10)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antihypertensive Agents/pharmacology/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Coenzymes
MH  - Diastole
MH  - Drug Therapy, Combination
MH  - Echocardiography
MH  - Female
MH  - Heart Ventricles/pathology
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Ubiquinone/*analogs & derivatives/pharmacology/therapeutic use
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.1016/0098-2997(94)90037-x [doi]
PST - ppublish
SO  - Mol Aspects Med. 1994;15 Suppl:S265-72. doi: 10.1016/0098-2997(94)90037-x.